HeartWare International (NSDQ:HTWR) shares closed up 2.4% today after the company won a hearing date before the FDA’s circulatory system devices panel in April.
The sympathetic vibrations generated by the news also drove up shares of heart-pump rival Thoratec and Edwards Lifesciences , which is awaiting news of its own review by the panel for one of the PMA applications for its Sapien replacement heart valve.